New weekly shot could boost growth in babies with dwarfism
NCT ID NCT06079398
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a weekly injection called TransCon CNP in infants under 2 years old with achondroplasia, the most common form of dwarfism. The goal is to see if it safely improves growth over 52 weeks. About 72 babies will take part, with some receiving the drug and others a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Navepegritide (TransCon CNP)
- What this could lead to
- If successful, this could lead to a treatment that improves growth in infants with achondroplasia, potentially reducing some complications of the condition.
- What could go wrong
- This is an early Phase 2 trial with only 72 infants, so results may not confirm benefit. Side effects are possible, and the treatment may not work for all.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACHONDROPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ascendis Investigational Site
RECRUITINGSaint Paul, Minnesota, 55102, United States
-
Ascendis Investigational Site
RECRUITINGHouston, Texas, 77030, United States
-
Ascendis Investigational Site
RECRUITINGMadison, Wisconsin, 53705, United States
-
Ascendis Investigational Site
RECRUITINGParkville, 3052, Australia
-
Ascendis Investigational Site
RECRUITINGLinz, 4020, Austria
-
Ascendis Investigational Site
RECRUITINGMontreal, H3T 1C5, Canada
-
Ascendis Investigational Site
RECRUITINGCopenhagen, 2100, Denmark
-
Ascendis Investigational Site
RECRUITINGHelsinki, 00029, Finland
-
Ascendis Investigational Site
RECRUITINGParis, 75743, France
-
Ascendis Investigational Site
RECRUITINGBerlin, 13353, Germany
-
Ascendis Investigational Site
RECRUITINGCologne, 50931, Germany
-
Ascendis Investigational Site
RECRUITINGDublin, D01 YC76, Ireland
-
Ascendis Investigational Site
RECRUITINGMilan, 20132, Italy
-
Ascendis Investigational Site
RECRUITINGAuckland, 1023, New Zealand
-
Ascendis Investigational Site
RECRUITINGOslo, 0372, Norway
-
Ascendis Investigational Site
RECRUITINGCoimbra, 3000-602, Portugal
-
Ascendis Investigational Site
RECRUITINGStockholm, 17176, Sweden
-
Ascendis Investigational Site
RECRUITINGLondon, SE1 7EH, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a weekly shot help children with achondroplasia grow taller?
- Can growth hormone boost height in children with dwarfism?
- Weekly shot may boost growth in kids with dwarfism
- Experimental achondroplasia drug trial halted early
- No treatment, just tracking: PROPEL study watches how kids with achondroplasia grow
- New drug aims to boost height in kids with dwarfism